: Previously struggling, this pharmacy chain's stock recovered significantly, moving back above the $5.00 mark. Goldman Sachs "Most Undervalued" Selections (May 2013)
: Yielded 3.3% ; identified as a top undervalued watch-list item in late 2013. Notable Sector Rebounds
: Yielded 3.3% and was considered undervalued with a low payout ratio.
: Noted for a record $5.39 billion in Q1 revenue with a projected 24.8% upside.
: A medical device maker that saw a breakout after cost-cutting and management shifts, rising 110% in 2013.